| Literature DB >> 23715941 |
V Di Marco1, F De Vita, J Koskinas, D Semela, P Toniutto, C Verslype.
Abstract
Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation. The approval of sorafenib for this indication was grounded on the efficacy and the safety results reported by two international randomized, controlled trials, the SHARP and the Asia-Pacific studies. In addition, the efficacy and the safety of sorafenib in clinical practice are addressed by several field-practice experiences, including the multinational GIDEON study and the SOFIA study. Finally, further research on sorafenib is ongoing to optimize the use of this molecule. This review aims to provide an overview of the most relevant clinical data on the efficacy and the safety of sorafenib in patients with HCC.Entities:
Keywords: adverse events; clinical practice; observational studies; randomized clinical trials; sorafenib
Mesh：
Substances：
Year: 2013 PMID： 23715941 DOI： 10.1093/annonc/mdt055
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976